Peptide Comparison
CJC-1295 vs Ipamorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
GH secretagogues combined with exogenous HGH: Moderate-High risk per peptide research literature. Negative feedback via somatostatin/IGF-1; risk of pituitary suppression; diminishing returns on GH output.
Use together
They aren't really competitors; they're meant to be paired. CJC-1295 is a GHRH analog (the upstream release signal at the pituitary). Ipamorelin is a ghrelin-receptor agonist (the pulse amplifier). The Gold Standard GH stack pairs them precisely because the pathways are complementary. If you must pick one alone: pick CJC-1295 for sustained GHRH-axis tone, pick ipamorelin for clean pulse amplification without the cortisol/prolactin/hunger spike that older GHRPs (GHRP-2/6, hexarelin) produce.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
The actual difference
CJC-1295 acts at the pituitary GHRH receptor, the upstream release signal. Ipamorelin acts at GHS-R1a, the ghrelin receptor and pulse amplifier. The two pathways converge on GH release through different second messengers, which is why the combination produces more GH than either alone. CJC-1295 also has two variants: no-DAC (~30 min half-life, multiple daily injections) and DAC (~8 day half-life, weekly).
Which one to pick
Pick CJC-1295 if
- Sustained GHRH-axis tone is the goal (DAC variant gives weekly dosing)
- Single-injection convenience matters more than peak pulse
- You're already running a GHRP from a different stack
Pick Ipamorelin if
- Pulse amplification without hunger, cortisol, or prolactin (the GHRP-2/6/hexarelin selectivity problem)
- You're stacking with exogenous GHRH (Tesamorelin or sermorelin) and need a clean GHRP
- Bedtime-only single injection alongside endogenous nocturnal GH pulse
Avoid both if
- Active malignancy (GH/IGF-1 elevation is a theoretical proliferation concern)
- Active diabetic retinopathy (IGF-1 implicated)
- Pregnancy
Used together in
- Gold Standard GH: GH pulse amplification
Shared safety considerations
Both compounds share these reported concerns: injection site reactions. Open each peptide page for the full risk paragraph and source citations.
Common confusions
- 'CJC-1295 and ipamorelin are interchangeable'. False. They're complementary, not redundant. The redundancy mistake is stacking two GHRHs (CJC + sermorelin) or two GHRPs (ipamorelin + GHRP-2).
- 'CJC-1295 with DAC and without DAC are the same drug'. False. No-DAC has a 30-minute half-life and demands multi-dose-daily protocols. DAC binds albumin for ~8 days and produces sustained signal. Different protocols, different effects on GH pulse architecture.
- 'Pairing produces 5x more GH'. Exaggerated. The cited synergy is roughly 2-3x either alone, not 5x. Forum copy frequently rounds this up.
Side-by-side
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | GHRH analog (no-DAC or DAC forms) | Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life | Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise |
| Route | SC injection | SC injection |
| Half-life | No-DAC ~30 min / DAC ~8 days | ~2 hrs |
| Dosage (research) | No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) | 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC) |
| Evidence tier | Anecdotal + Phase 2 (DAC) | Anecdotal + Phase 2 |
| Research depth | 57 indexed | 91 indexed |
| Availability | Compounding Restricted | Compounding Restricted |
| Reported risks | Water retention; numbness/tingling; elevated IGF-1; injection site reactions | Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CJC-1295 or Ipamorelin?
They aren't really competitors; they're meant to be paired. CJC-1295 is a GHRH analog (the upstream release signal at the pituitary). Ipamorelin is a ghrelin-receptor agonist (the pulse amplifier). The Gold Standard GH stack pairs them precisely because the pathways are complementary. If you must pick one alone: pick CJC-1295 for sustained GHRH-axis tone, pick ipamorelin for clean pulse amplification without the cortisol/prolactin/hunger spike that older GHRPs (GHRP-2/6, hexarelin) produce.
What is the difference between CJC-1295 and Ipamorelin?
CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); Ipamorelin is classed as Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist. Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; Ipamorelin, Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise. Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; Ipamorelin, ~2 hrs. Routes in published studies: CJC-1295, SC injection; Ipamorelin, SC injection.
Which has stronger evidence, CJC-1295 or Ipamorelin?
CJC-1295 and Ipamorelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 57 indexed studies. Ipamorelin is graded Anecdotal + Phase 2, with 9 cited sources on its reference page and 91 indexed studies.
Which is more accessible, CJC-1295 or Ipamorelin?
Neither CJC-1295 nor Ipamorelin is an FDA-approved drug. Catalog status: CJC-1295, Compounding Restricted; Ipamorelin, Compounding Restricted. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn. FDA lists Ipamorelin in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are CJC-1295 and Ipamorelin ever combined?
Yes. Gold Standard GH is a documented stack containing both CJC-1295 and Ipamorelin; the stack page gives the stated rationale.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…